$COR

Camino Minerals (COR) announced its Puquios copper project in Chile has entered detailed engineering with Ausenco Chile. The company is also exploring a potential Japanese debt facility with Nittetsu to fund construction, following the completion of a critical phase study.

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

Argus raised its price target on Cencora Inc. (NYSE:COR) to $380, citing sustainable earnings growth and an attractive valuation. The company reported Q3 2026 adjusted earnings of $4.48 per share on $84.8 billion revenue, exceeding expectations. Cencora increased its full-year profit outlook despite some Walgreens volume moving away. RBC Capital maintained a Sector Perform rating with a $330 price target, noting growth in specialty pharma but lacking high-margin businesses.

Camino Minerals' JV Cuprum received DGA authorization to start water works at the Puquios copper project in Chile after posting a $1.7M bond. The bond will be returned post-construction and certification.

Cencora (COR) appointed Robert E. Sanchez as an independent director. The stock is trading at $309, with mixed recent performance: -6.62% over 30 days, +3.52% over 90 days, and +2.86% over one year. Analysts suggest it may be undervalued at a fair value of $369, citing growth in specialty services. However, risks include biosimilar fee pressure and customer contract shifts.

Cencora, Inc. (COR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Press Release CENCORA ELECTS ROBERT E. SANCHEZ TO ITS BOARD OF DIRECTORS CONSHOHOCKEN, PA, September 25, 2026 — Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 202

Cencora (NYSE:COR) reported elevated prescription utilization trends rebounding in March, with most Walgreens business under its primary contract. The company expects accelerating growth in Q4, focusing on oncology and retina specialties. Cencora acquired the remaining interest in OneOncology, citing synergies with Retina Consultants of America. Management discussed biosimilars, policy impacts, and international growth, maintaining capital allocation priorities.

Cencora's CFO Eva Boratto, formerly of Merck and CVS Health, highlighted the company's growth strategy in specialty pharmaceuticals and MSO expansion. She praised the clear strategy and the company's role in the pharmaceutical market. Cencora expects its MSO business to grow, focusing on retina and oncology. The company also discussed its clinical trial support and capital allocation priorities, including investments in MSO platforms and opportunistic share repurchases.

Cencora (COR) reported Q3 revenue of $84.8B (+5.1%) and adjusted EPS of $4.48 (+12.0%). The company raised its full-year adjusted EPS outlook to $17.75-$17.95 and repurchased $1B in stock. Adjusted operating income rose 17.0%, driven by gross profit growth and the OneOncology acquisition. However, operating expenses increased 26.8%, and financing costs rose due to new debt. Lower-margin GLP-1 drugs and lost customers impacted revenue growth.